Immunology
Mavatar announces research collaboration with Sobi
January 6, 2026Research and Development Immunology, Mavatar, Rare Diseases, sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …
STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases
December 18, 2025Research and Development Bio-Thera, Immunology, Stada
STADA and Bio-Thera’s Gotenfia (golimumab), a biosimilar of Janssen’s Simponi, has received a positive opinion from the European Medicines Agency …
Celltrion’s Remsima IV approved by EC in liquid form
November 27, 2025Research and Development Celltrion Inc, Immunology
Celltrion’s Remsima IV, the first-ever liquid formulation of infliximab for autoimmune diseases, has been approved by the European Commission (EC). …
Alvotech biosimilar receives EC marketing approval
November 26, 2025Research and Development Alvotech, Immunology, Inflammatory disease, Rheumatology
The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotech’s first-in-market biosimilar of Simponi (golimumab), which is used for …
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
October 3, 2025Medical Communications, Research and Development Dermatology, Immunology, acute urticaria, chronic spontaneous urticaria, dermatology, immunology
The current forms of immunotherapy, how T cell therapy works and what the future holds
Neogap Therapeutics appoints Jonas Mattson to its board of directors
August 26, 2025Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors
Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …
NICE recommends Benralizumab for Rare Form of Vasculitis
August 15, 2025Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
Novartis candidate for Sjögren’s disease presents positive results
August 15, 2025Research and Development Immunology, Novartis, Sjögren’s disease, US Food and Drug Administration, clinical trial
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab in adults …
CuraCell granted approval for trial of new therapy for metastatic cancers
August 13, 2025Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer
Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
August 3, 2025Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
July 29, 2025Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …
Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes
July 10, 2025Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …
Richard Philipson appointed as chief medical officer of Hansa Biopharma
July 9, 2025Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology
Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
June 30, 2025Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
